<DOC>
	<DOCNO>NCT01240447</DOCNO>
	<brief_summary>This study design evaluate safety immunogenicity racotumomab patient advance Non-small Cell Lung Cancer ( NSCLC ) , concomitance chemotherapy ( docetaxel ) second-line therapy indicate . The study also compare survival progression free survival study arm .</brief_summary>
	<brief_title>Immunotherapy With Racotumomab Versus Support Treatment Advanced Non-small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . The patient ( age 21 year , either sex ) comply protocol schedule appointment sign voluntarily inform consent form 2 . Diagnosis Nonsmall cell lung cancer ( NSCLC ) stag IIIA ( surgically unresectable ) , IIIB IV , accord TNM classification ( TumorNodesMetastases ) version 6a , confirm cytology histology , possible available determination ganglioside expression 3 . Patients may enter study accomplished objective response ( complete response partial response ) disease stabilisation ( Response Evaluation Criteria In Solid Tumours [ RECIST ] ) completion standard oncospecific treatment . In case , response document . For stage IIIA IIIB without pleural effusion ( `` dry IIIB '' ) standard treatment consider follow : 2 4 cycle platinumbased chemotherapy and/or radiotherapy curative intent accordance National Comprehensive Cancer Network ( NCCN ) guideline For stage IIIB pleural effusion ( `` wet IIIB '' ) stage IV standard treatment consider follow : 4 6 cycle chemotherapy base platinum . In case pleural pericardial effusion require local treatment , provide prior study entry . 4 . Patients interval great 30 90 day completion oncospecific treatment study entry . Completion treatment define last day administration chemotherapy last day radiotherapy . Patients recover related episode acute toxicity degree great 1 ( except alopecia ) . Patients receive monoclonal antibody ( eg bevacizumab ) also discontinue use least 30 day inclusion . 5 . The subject male female , age great equal 21 year 6 . Performance status ( Eastern Cooperative Oncology Group [ ECOG ] ) less equal 1 7 . Acceptable organ functionality define follow parameter : Electrocardiogram ( ECG ) without significant abnormality , perform within 14 day prior admission Haemoglobin great equal 90 g/L Total leukocyte count great equal 3.0 x 10^9/L Absolute neutrophil count great equal 1.5 x 10^9/L Total bilirubin less equal 1.5 time upper limit normal twice limit normal case liver metastases present Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) less equal 2.5 time upper limit normal ( less equal five time normal maximum case liver metastasis present ) Creatinine le equal 2 mg/dL 8 . Life expectancy least four month 1 . Patient pregnant breastfeeding 2 . Has receive chemotherapy , radiotherapy , immunotherapy surgery within 30 day prior inclusion 3 . Hypersensitivity component formulation 4 . Patients childbearing potential either sex use adequate method contraception treatment avoid pregnancy ( partner ) . For female : intrauterine device , hormonal contraceptive , barrier method sterilisation . For male : vasectomy condom spermicide . 5 . Patients receive receive investigational drug 30 day prior study entry 6 . History autoimmune diseases 7 . Decompensated chronic disease 8 . Acute allergic disorder history severe allergic reaction 9 . Known brain metastasis uncontrolled surgery and/or radiation therapy current corticosteroid therapy 10 . History inflammatory demyelinate disease central peripheral nervous system 11 . Uncontrolled intercurrent illness , include active infection , symptomatic congestive heart failure , unstable angina cardiac arrhythmia psychiatric disease imply patient incompetence 12 . Other malignancy , exception basal cell carcinoma , situ cervical carcinoma , incidental prostate cancer ( T1a , Gleason le equal 6 , prostate specific antigen [ PSA ] le 0.5 ng/ml ) , tumour tumour adequately treat diseasefree period great equal 5 year 13 . Chronic treatment systemic corticosteroid dos great 0.5 mg/kg/day maximum 40 mg/day prednisone equivalent 14 . The subject history drug abuse ( illicit drug ) alcohol abuse ( define regular periodic ingestion four drink day ) last 2 year 15 . Positive serology hepatitis B , C know human immunodeficiency virus ( HIV ) infection 16 . Uncontrolled hypercalcaemia great equal 2.9 mmol/L ( grade great 1 accord Common Terminology Criteria Adverse Events [ CTCAE ] version 3.0 )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>lung cancer , small-cell</keyword>
	<keyword>advanced lung cancer</keyword>
</DOC>